MedTrace Logo

Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation

NCT04934410 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-10-19

No results posted yet for this study

Summary

The induction of anesthesia is one of the most critical situations for high-risk-patients undergoing major surgery. For several reasons, it is crucial to maintain adequate blood pressure and cardiac output during this phase.

This observational study aims to find out if the choice of the induction agent has a major impact on blood pressure and the use of antihypotensive drugs during the induction and the surgical procedure in heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD).

Conditions

  • Blood Pressure, Low

Interventions

DRUG

Etomidate

Use of etomidate during induction as decided by attending anesthesiologist

DRUG

Midazolam

Use of midazolam during induction as decided by attending anesthesiologist

DRUG

Sevoflurane

Use of sevoflurane during induction as decided by attending anesthesiologist

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Adrian E Stephan, MD · Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04934410 on ClinicalTrials.gov